Comparative safety of drug therapies used in hemophilia A and B in Canada: a multi-center, retrospective study.

ABSTRACT:

Background

Comparative safety data on hemophilia therapies are scarce.

Objectives

To compare the risk of adverse drug reactions (ADRs) associated with extended-half-life (EHL) and standard-half-life (SHL) clotting factor therapies, bypassing agents, and emicizumab.

Methods and analysis

We analyzed Canadian Bleeding Disorders Registry data from 2018 to 2022. ADRs were defined as adverse events (AEs) if definitely, possibly, or probably treatment-related. We compared incidence rates of ADRs between therapies to estimate incidence rate ratios and 95% CIs.

Results

We found a total of 183 AEs and 67 ADRs. Reported AEs varied from 6.1 to 14.8 events per 1000 patients per year. Allergic reactions were the most prevalent ADRs. A higher incidence of allergic reactions w

SUBMITTER: Olasupo OO 

PROVIDER: S-EPMC12799776 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature